Chantal Pharmaceutical's cyoctol
Firm announces IND approval to begin clinicals for cyoctol use in the treatment of male pattern baldness. Initial testing will be conducted at UCLA. Chantal described cyoctol as a synthetic, nonsteroidal anti-androgen that is part of a series of Chantal compounds known as X-Androns. Clinicals are also underway investigating cyoctol use in treatment of acne vulgaris and the company plans to file an IND in 1987 for keloid scar prevention ("The Pink Sheet" Oct. 13, T&G-7).
You may also be interested in...
Washington State Ecology Mulls ‘Safer’ Definition While Exploring Phthalate Alternatives In Fragrances
Marissa Smith, senior regulatory toxicologist in the Washington Department of Ecology’s Hazardous Waste and Toxics Reduction program, discusses what’s next for the state’s inaugural Safer Products go-round. “How we define ‘safer’ is really going to be the lynchpin of this whole process,” she says.
Class action complaints filed in 2020 against food, dietary supplement and beverage firms should pass 2019’s total as COVID-19 has not slowed litigants but has given plaintiffs’ council more time out of court to shop for new cases.
The new continuous glucose sensor is the smallest and thinnest in the world, according to Abbott.